RecruitingPrader-Willi SyndromeHypothalamic ObesityObesity/Therapy
Tirzepatide in PWS, HO and GNSO
Eligible age
18–26 yrs
Accepts
All genders
Locations
3 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This research study is comparing the effectiveness of a weight loss medication called Tirzepatide in young adults with Prader-Willi Syndrome and/or hypothalamic obesity, as compared to young adults with obesity that is unrelated to a genetic syndrome or underlying medical cause. These groups will be given medication for 1 year to see how weight and other health factors are effected by the medication.
Sponsor: Grace Kim
You may qualify if…
- ✓ Individuals 18-26 years with a BMI in the obesity range (BMI ≥95th percentile for age and sex or ≥30 kg/m2) with either 1) genetically confirmed diagnosis of PWS, 2) hypothalamic obesity as defined by damage to the medial hypothalamic region resulting in dysregulation of satiety and energy balance as diagnosed by a physician, 3) general obesity unrelated to a genetic syndrome or underlying medical condition
- ✓ In a stable care setting at least 6 months prior to enrollment
- ✓ Able and willing to participate in study visits including tolerating blood draws, urine samples and tolerate DXA scan.
- ✓ Ability to take weekly subcutaneous tirzepatide
- ✓ Consistent caregiver if they are not independent
- ✓ Stable diet and exercise regimen for at least 6 months prior to enrollment
- ✓ Able to use contraceptive methods if able to conceive offspring in order to prevent unintentional pregnancy during the study
You may not qualify if…
- ✕ Current or recent (within 3 months of start of study drug initiation) use of weight loss medications
- ✕ Current use of insulin or sulfonylurea or other medication affecting insulin secretion or GLP1 clearance
- ✕ Current or prior use of any GLP1A or DPP4 inhibitor during the 6 months before screening
- ✕ Any medications that may affect the study endpoints
- ✕ Significant weight change (\>3% weight gain or loss) in the last 2 months prior to enrollment
- ✕ Change in dose of chronic endocrine medications (testosterone, estrogen, levothyroxine, or growth hormone medications) \>10%/kg/day for at least 3 months prior to study
- ✕ Current pregnancy or desire to become pregnant within study period, current lactation
- ✕ History of recurrent pancreatitis, CKD, gastroparesis
Where it's recruiting
Source: ClinicalTrials.gov · NCT06901245 · last updated 2025-09-16